Avantor Inc., a global provider of products and services to customers in the life sciences, is increasing global capacity for single-use technologies used in the production of biologics and vaccines.   In the U.S. and Europe, the company will increase its single-use manufacturing footprint by 30% and double its cleanroom space. The investment will support growing customer demand for monoclonal antibodies (mAbs), novel cell and gene therapies for oncology and other diseases, as well as vaccines...